Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cartesian Therapeutics (RNAC) Research & Development (2016 - 2025)

Cartesian Therapeutics (RNAC) has disclosed Research & Development for 11 consecutive years, with $14.7 million as the latest value for Q4 2025.

  • Quarterly Research & Development rose 29.92% to $14.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $58.0 million through Dec 2025, up 28.66% year-over-year, with the annual reading at $58.0 million for FY2025, 28.66% up from the prior year.
  • Research & Development for Q4 2025 was $14.7 million at Cartesian Therapeutics, up from $13.8 million in the prior quarter.
  • The five-year high for Research & Development was $21.9 million in Q4 2023, with the low at $9.7 million in Q1 2024.
  • Average Research & Development over 5 years is $15.8 million, with a median of $14.8 million recorded in 2025.
  • The sharpest move saw Research & Development crashed 48.26% in 2024, then soared 50.69% in 2025.
  • Over 5 years, Research & Development stood at $20.3 million in 2021, then fell by 6.65% to $19.0 million in 2022, then grew by 15.21% to $21.9 million in 2023, then plummeted by 48.26% to $11.3 million in 2024, then rose by 29.92% to $14.7 million in 2025.
  • According to Business Quant data, Research & Development over the past three periods came in at $14.7 million, $13.8 million, and $14.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.